Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Pacer Advisors Inc.

Pacer Advisors Inc. increased its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 9.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 45,298 shares of the company’s stock after acquiring an additional 3,930 shares during the quarter. Pacer Advisors Inc.’s holdings in Moderna were worth $5,379,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC purchased a new position in Moderna during the second quarter worth approximately $26,000. Cedar Wealth Management LLC raised its stake in Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the period. Westside Investment Management Inc. purchased a new position in Moderna during the first quarter worth approximately $32,000. Family Firm Inc. purchased a new position in Moderna during the second quarter worth approximately $33,000. Finally, Rise Advisors LLC raised its stake in Moderna by 953.3% during the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after purchasing an additional 286 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of MRNA stock opened at $64.14 on Tuesday. The firm has a market cap of $24.58 billion, a P/E ratio of -4.09 and a beta of 1.67. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47. The firm has a fifty day moving average of $88.92 and a two-hundred day moving average of $110.71.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm’s revenue for the quarter was down 29.9% compared to the same quarter last year. During the same period last year, the business earned ($3.62) EPS. As a group, research analysts anticipate that Moderna, Inc. will post -9.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on MRNA. Jefferies Financial Group downgraded shares of Moderna from a “buy” rating to a “hold” rating and cut their price target for the stock from $120.00 to $65.00 in a research note on Friday, September 13th. Oppenheimer downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Friday, September 13th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and cut their target price for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Finally, William Blair reissued a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $100.44.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 689 shares of Moderna stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the transaction, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Mock sold 689 shares of Moderna stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the completion of the transaction, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at $859,486.56. The disclosure for this sale can be found here. Insiders sold a total of 93,158 shares of company stock valued at $11,167,312 in the last ninety days. Corporate insiders own 15.70% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.